Trial reportLeukemia2007
Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.
Trial report in Leukemia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 62 citations in OpenAlex.
- Acute promyelocytic leukemia with secondary myelofibrosis and positive CD34 expression.International journal of clinical and experimental pathology · 2026Article
- EarlyCancers · 2025Article
- Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukaemia patients initially treated with imatinib: An extensive, multicenter and retrospective study to develop a prognostic model.Clinical and translational medicine · 2024Article
- Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients.Frontiers in pharmacology · 2023Article
- Cancer non-stem cells as a potent regulator of tumor microenvironment: a lesson from chronic myeloid leukemia.Molecular biomedicine · 2021Review
- Definition, Epidemiology, Pathophysiology, and Essential Criteria for Diagnosis of Pediatric Chronic Myeloid Leukemia.Cancers · 2021Review
- Chronic Myeloid Leukemia in 2020.HemaSphere · 2020Review
- Review
- Early Management of CML.Current hematologic malignancy reports · 2019Review
- Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI.Blood advances · 2019Article
- The underestimated role of basophils in PhEuropean journal of clinical investigation · 2018Review
- Article
- Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.Haematologica · 2016Review
- Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance.The Journal of experimental medicine · 2013Article
- Rapid Evolution to Blast Crisis Associated with a Q252H ABL1 Kinase Domain Mutation in e19a2 BCR-ABL1 Chronic Myeloid Leukaemia.Case reports in hematology · 2013Article
- IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.Cancer cell · 2011Article
- Article
- The bone marrow stroma in hematological neoplasms--a guilty bystander.Nature reviews. Clinical oncology · 2011Review
- Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome.Leukemia · 2008Article
- Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes.Leukemia · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In chronic myeloid leukemia (CML), imatinib may reverse bone marrow fibrosis (MF). Whether the unfavorable prognosis of MF is also reversed and whether imatinib guarantees against evolution of MF are unclear as yet. Fifty-nine patients with Ph+ CML treated with > or = 400 mg imatinib/day were examined for MF in 6- to 12-month intervals. Imatinib effectively reversed initial MF (P<0.0005). However, during a follow-up period of up to 4.8 years, small foci with abnormal fiber increase (FFI) emerged in 8 of 30 pretreated and 6 of 29 non-pretreated patients. Patients with FFI showed a significantly lower probability of achieving a complete cytogenetic or major molecular response (36 versus 81%; P<0.007). During the further follow up, 57% of patients with FFI but none of the other patients suffered from full-blown MF (P=0.00005). None of the patients with FFI or MF showed a Janus kinase-2 mutation (V617F). Evolutions of FFI and MF were independent significant predictors of imatinib failure (P=0.0031), accelerated phase and death of patients (P=0.0001; multivariate analyses). Imatinib effectively reverses initial MF in CML, but neither eliminates its unfavorable prognosis nor guarantees completely against new evolution of MF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.